EPIX Pharma (EPIX) Initiates Phase 2b Program in Alzheimer's Disease
More News related to EPIX
- EPIX Pharmaceuticals Announces Noteholders' Right to Require the Company to Repurchase $3.2 Million Outstanding Balance of 3% Convertible Senior Notes Due 2024
- EPIX Pharmaceuticals Announces Receipt of NASDAQ Panel Decision to Delist Common Stock
- EPIX Pharma (EPIX) Reports Mixed Q1 Results
- EPIX Pharmaceuticals Announces First Quarter 2009 Financial Results
- Needham & Co Downgrades EPIX Pharmaceuticals (EPIX) to Hold
More News related to FDA
- Caraco Pharmaceutical Laboratories (CPD) Announces Its Reducing Its Workforce By 350 Employees
- Covidien (COV) Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit
- CombinatoRx (CRXX) Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations
- Spectrum Pharmac (SPPI) Receives Complete Response Letter from FDA for Zevalin
- Lilly (LLY) Receives Fourth FDA Approval for ALIMTA
EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) has begun its Phase 2b program in Alzheimer's disease through the initiation of a clinical trial of PRX-03140, its novel 5-HT4 agonist, in combination with donepezil.
Under the company's collaboration agreement with GlaxoSmithKline (GSK), EPIX is entitled to receive a $7.5 million milestone payment from GSK related to the start of the Phase 2b program for PRX-03140 in Alzheimer’s disease.
Related Categories
FDAStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
